Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback